| Literature DB >> 33737816 |
Thomas Bahmer1,2, Henrik Watz3, Mustafa Abdo1, Benjamin Waschki4, Anne-Marie Kirsten3, Frederik Trinkmann5,6, Heike Biller1, Christian Herzmann7, Erika von Mutius8, Matthias Kopp9,10, Gesine Hansen11, Klaus F Rabe1.
Abstract
RATIONALE: Asthma, obesity and physical activity (PA) are interrelated. However, longitudinal data with objective PA measures and direct assessment of body composition are still lacking.Entities:
Keywords: BMI; body composition; fat mass; muscle mass; physical activity; symptom control
Year: 2021 PMID: 33737816 PMCID: PMC7966302 DOI: 10.2147/JAA.S299756
Source DB: PubMed Journal: J Asthma Allergy ISSN: 1178-6965
Baseline Clinical Characteristics of Patients with Asthma and Healthy Controls
| Characteristics | Healthy Controls | Controlled Asthma | Uncontrolled Asthma | P-value |
|---|---|---|---|---|
| n | 84 | 106 | 127 | – |
| Age, years | 46.2 ±18.6 | 51.2 ±13.5 | 52.6 ±14.5 | 0.015* |
| Sex (% male) | 53 | 45 | 41 | 0.20 |
| BMI (kg/m2) | 24.9 ±4.0 | 26.7 ± 4.4 | 28.5 ±5.5 | <0.0001 |
| Smoking history, % | 19 | 21 | 25 | 0.54 |
| ICS (%) | – | 12 | 8 | 0.08 |
| ICS/LABA (%) | – | 76 | 92 | 0.09 |
| ICS dose (µg) | – | 408 ±309 | 748 ±535 | <0.0001 |
| LAMA (%) | – | 13 | 42 | <0.0001 |
| OCS (%) | – | 14 | 32 | <0.0001 |
| Biological therapy (%) | – | 8 | 16 | <0.001 |
| FEV1% | 103 ±11 | 88 ±18 | 72 ±20 | <0.0001 |
| FEV1/FVC (%) | 76 ±7 | 68 ± 11 | 60 ±13 | <0.0001 |
| PEF (l/s) | 9.0 ±2.0 | 7.6 ±2.2 | 6.1 ± 2.0 | <0.0001 |
| ACT score | – | 23.0 ±1.7 | 13.5 ±4.0 | <0.0001 |
| ACQ5 score | – | 0.56 ±0.49 | 2.33 ±1.1 | <0.0001 |
| Severe exacerbations in the previous 12 months | – | 0 (0.0–1.0) | 2 (0.0–5.0) | <0.0001 |
| Average daily steps | 7839 (6577–9430) | 7806 (6337–10,004) | 6641 (4886–9280) | <0.001 |
| Average daily time of at least moderate activity, min | 132 (72–175) | 133 (93–192) | 108 (54–183) | 0.012 |
| SM (%) | 36±7.0 | 34 ±6.0 | 32 ±6.0 | <0.0001 |
| FM (%) | 30 ±7.0 | 32 ±7.0 | 35 ±7.0 | <0.0001 |
Notes: Values are presented in mean and standard deviation or median and interquartile range. *Post hoc analysis: controlled asthma vs uncontrolled p=0.75, controlled asthma vs healthy controls p=0.088, uncontrolled asthma vs healthy controls p=0.012. Physical activity was similar between controlled asthma and healthy controls.
Abbreviations: BMI, body mass index (kg/m2); smoking history, current or former smoker >10 pack years; ICS dose, inhaled corticosteroids fluticasone equivalent (µg); LABA, long-acting β2-adrenoceptor agonists; LAMA, long-acting muscarinic receptor antagonists; OCS, regular daily oral corticosteroid therapy; biological therapy, omalizumab or mepolizumab; FEV1, predicted forced expiratory volume in the 1 second; FVC, forced vital capacity; PEF, peak expiratory flow (l); ACT, asthma control test; ACQ, asthma control questionnaire; SM, skeletal muscle mass; FM, fat mass.
Clinical Characteristics of Asthma Patients Based on Skeletal Muscle Mass and Gender
| Parameter | Males | Females | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| First Quartile | Second Quartile | Third Quartile | Fourth Quartile | P-value | First Quartile | Second Quartile | Third Quartile | Fourth Quartile | P-value | |
| SM quartile | <33.5 | 33.5–36.9 | 37.0 40.9 | ≥41 | – | <26.3 | 26.4–28.8 | 28.9–32.6 | >32.6 | – |
| n | 22 | 30 | 27 | 21 | – | 28 | 40 | 27 | 38 | – |
| Age, years | 59.9 ±11.4 | 54.4 ±14.6 | 54.0 ±11.1 | 49.0 ±13 | 0.06 | 54.3 ±11 | 54.4 ±14 | 48.7 ±12.9 | 43.7 ±16 | <0.01 |
| SM (%) | 31 ±2 | 35 ±1 | 39 ±1 | 44 ±2 | <0.01 | 24 ±2 | 28 ±1 | 30 ±1 | 36 ±4 | <0.01 |
| BMI (kg/m2) | 32.8 ±3.8 | 28.2 ±2.6 | 27.4 ±3.7 | 25.2 ± 2.9 | <0.01 | 34.7 ±5.0 | 27.5 ±4.1 | 25.6 ±2.8 | 22.3 ±2.8 | <0.01 |
| FM (%) | 37 ±3 | 31 ±1 | 27 ±2 | 21 ±2 | <0.01 | 46 ±3 | 39 ±3 | 36 ±2 | 29 ±6 | <0.01 |
| ACQ5 score | 1.9 ±1.2 | 1.44 ±1.2 | 1.20 1.0 | 0.96 ± 0.9 | 0.03 | 2.3 ±1.5 | 1.8 ±1.5 | 1.3 ±1.1 | 1.2 ±1.1 | <0.01 |
| ACT score | 15.9 ±4.8 | 18.0 ±6.1 | 19.2 ±4.8 | 20.0 ±5.2 | 0.06 | 14.7 ±5.4 | 17.2 ±5.9 | 18.4 ±5.8 | 18.9 ±5.4 | 0.02 |
| FEV1 (%) | 72 ±14 | 81 ±24 | 77 ±18 | 99 ±20 | 0.52 | 73 ±20 | 81 ±28 | 83 ±18 | 85 ±21 | 0.14 |
| FEV1/FVC (%) | 59 ±13 | 64 ±11 | 60 ±11 | 62 ±12 | 0.41 | 62 ±12 | 65 ±14 | 66 ±12 | 68 ±13 | 0.39 |
| PEF (l/s) | 7.4 ±2.6 | 8.00 ±2.5 | 8.1 ±2.3 | 8.2 ±2.5 | 0.74 | 5.9 ±1.7 | 5.9 ±1.7 | 5.8 ±1.1 | 6.0 ±1.6 | 0.9 |
| ICS dose (µg) | 775 (400–1000) | 500 (250–900) | 500 (250–1000) | 400 (250–500) | 0.04 | 695 (460 −1000) | 500 (500–1000) | 500 (250–500) | 450 (118–500) | 0.01 |
| OCS, (%) | 22 | 14 | 30 | 27 | 0.55 | 48 | 25 | 22 | 10 | 0.02 |
Notes: Values are in mean ±sd except for ICS due to skewness are represented in median and IQR. A post hoc analysis showed statistically significant differences in age only between the first and fourth/first and third quartiles in females. In females, the differences in the ACQ5 score were significant between the first and fourth, first and third quartiles, while the difference of ACT score was significant only between the first and fourth quartiles. In males, the ACQ5 was significantly different only between the first and fourth quartiles.
Abbreviations: SM, skeletal muscle mass; BMI, body mass index (kg/m2); FM, fat mass; ACQ, asthma control questionnaire; ACT, asthma control test; FEV1, predicted forced expiratory volume in the 1 second; FVC, forced vital capacity; PEF, peak expiratory flow (l); ICS dose, inhaled corticosteroids fluticasone equivalent (µg); OCS, oral corticosteroid; OCS, regular daily oral corticosteroid therapy.
Figure 1Physical activity in asthma patients in relation to skeletal muscle mass quartiles and gender: (A) the distribution of average daily steps in muscle mass quartiles. (B) the distribution of at least daily time in moderate activity according to muscle mass quartiles. In females, the post hoc analysis showed statistically significant differences in means of average daily steps between the first and fourth quartiles (p<0.0001), first and third quartiles (p=0.005), and second and fourth quartiles (p=0.01), (A, upper panel). The average daily time of at least moderate activity was significantly different between all quartile (p<0.001) except between the second and third quartiles (p=0.08) (B, upper panel). In males, average daily steps were only significantly different between the first and fourth quartiles (p=0.031), and between the second and fourth quartiles (p=0.002) (A, lower panel). Likewise, the average daily time of at least moderate activity was also significantly different between the first and fourth (p=0.031), and between the second and fourth quartiles (p=0.026) (B, lower panel).
Predictors of Body Composition in Asthma
| Male sex | 2.748 e−02 | 4.774e−03 | <0.001 |
| ACT score | 1.186 e−03 | 5.139 e−04 | 0.021 |
| Age | −6.497 e−04 | 1.646 e−04 | <0.001 |
| Physical activity | 2.913 e−04 | 2.738 e−05 | <0.001 |
| OCS use | −9.242 e−03 | 6.142 e−03 | 0.16 |
| ICS dose | −5.031 e−06 | 5.073e−06 | 0.40 |
| Intercept | 2.748 e−01 | 1.031e−02 | <0.001 |
| Male sex | −7.77 e−02 | 5.994 e−03 | <0.001 |
| ACT score | −1.452 e−03 | 6.237 e−04 | 0.021 |
| Age | 3.355 e−04 | 2.089 e−04 | 0.15 |
| Physical activity | −3.993 e−04 | 3.419 e−05 | <0.001 |
| OCS use | 1.369 e−02 | 9.083 e−03 | 0.080 |
| ICS dose | 6.385 e−05 | 8.533 e−06 | 0.38 |
| Intercept | 4.292 e−01 | 1.451 e−02 | <0.001 |
Notes: Multivariate regressions including predictors of SM: multiple R2=0.61, p< 0.0001, and predictors of fat mass: multiple R2=0.61, p< 0.0001. Age in years, sex: being male. In alternative regressions that did not include the ACT score as predictors, OCS use and ICS dose were significant predictors of muscle mass and fat mass ().
Abbreviations: ACT, asthma control test; OCS, regular oral corticosteroid use (categorical variable); physical activity, average daily time in moderate activity in minutes; ICS dose, fluticasone equivalent in µg.
Measures of Body Composition, Physical Activity and Symptom Control at Baseline and Follow-Up
| Parameter | Persistent Uncontrolled | Controlled or Transitionally Uncontrolled | ||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Follow-Up | Mean Difference | P-value | Baseline | Follow-Up | Mean Difference | P-value | |
| BMI (kg/m2) | 28.5 ±4.9 | 28.7 ±5.0 | +0.20 | 0.39 | 26.6 ±4.6 | 26.7 ±4.5 | +0.10 | 0.66 |
| FM (%) | 34.6 ±7 | 35.8 ±7 | +1% | 0.015 | 32.3 ±6 | 32.7% ±6 | 0.0 | 0.29 |
| FM (kg) | 30.1 ±10.0 | 31.2 ±10.0 | +1.06 | 0.012 | 25.8 ±8.51 | 26.2 ±8.2 | +0.4 | 0.45 |
| SM (%) | 32.2 ±6 | 31.0 ±6 | −1.2% | <0.01 | 33.8 ±5 | 33.5% ±5 | −0.3% | 0.30 |
| SM (kg) | 27.39 ±6.7 | 26.51 ±6.4 | −0.88 | <0.01 | 26.8 ±6.7 | 26.7 ±6.9 | −0.1 | 0.53 |
| Daily steps | 6614 ±2854 | 6195 ±2642 | −445 | 0.14 | 8670±3723 | 9058 ±3610 | +195 | 0.56 |
| Moderate activity | 118 ±75 | 115 ±79 | −3.0 | 0.11 | 156 ± 85 | 153 ±81 | −3.0 | 0.43 |
| FEV1 (%) | 73 ±20.0 | 71 ±20.0 | −1.9% | 0.33 | 86 ±20 | 84 ± 20 | −2% | 0.11 |
| ACQ5 score | 2.27 ±1.13 | 2.47 ±1.13 | +0.17 | 0.29 | 0.85 ±0.8 | 0.81 ±0.7 | −0.06 | 0.54 |
| ACT score | 13.12 ±4.24 | 14.14 ±3.5 | +1.02 | 0.08 | 21.1 ±3.8 | 21.8 ±2.9 | +0.69 | 0.10 |
Notes: Values are presented in mean and standard deviation. P-values are from either paired t-test or paired Wilcoxon test and represent the statistical significance of the longitudinal change of the tested measures.
Abbreviations: SM, skeletal muscle mass (skeletal muscle mass/total body mass x %); BMI, body mass index kg/m2; FM, fat mass to total body mass %; ACQ, asthma control questionnaire; ACT, asthma control test; FEV1, predicted forced expiratory volume in the 1 second.
Figure 2Longitudinal differences in muscle mass (A) average daily steps (B) and time of at least moderate activity (C) between persistent uncontrolled and controlled asthma patients at baseline and follow-up. Patients with persistent uncontrolled asthma had lower muscle mass (A), lower average daily steps (B) and time in at least moderate activity (C) at baseline and at follow-up p<0.01 compared to the rest of patients.